Trial reportJournal of cosmetic dermatology2026
A Split-Scar Study: Study of Surgical Scar Using Exosomes.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular mechanisms governing exosome biogenesis, engineering strategies, and emerging role as cell-free therapeutics.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExosomes have emerged as a promising therapeutic agent for various dermatological conditions such as acne, atopic dermatitis, and wound healing. This study aims to evaluate exosome's efficacy in improving postoperative scars.
methodsTen patients underwent revision rhinoplasty with autologous costal cartilage, each with a 3 cm anterior chest incision scar were enrolled. Scars (mean 4.3 months postoperatively) were divided into medial and lateral halves; one half was treated with ASC-Exosome (experimental) and the other with hyaluronic acid (control). Outcomes were assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS).
resultThe experimental side treated with ASC-Exosome demonstrated improvements compared to the control side. Pigmentation improved significantly in the Observer Scar Assessment Scale (OSAS) group from week 3 onward, though no consistent changes were observed on the VSS. Pliability showed significant improvement in both OSAS and VSS, beginning at week 3 and persisting through week 8. Relief also improved in the OSAS group from weeks 4 to 8. While no vascularity differences were detected, one-year follow-up photographs confirmed superior improvements in scar height and thickness on the exosome-treated side. Patient Scar Assessment Scale (PSAS) indicated significant improvements in scar color by week 4, stiffness by week 3, and thickness by week 2. Irregularity showed significant differences at week 4 and week 8. No significant differences were noted in pain or itching between the sides.
conclusionsExosomes significantly improved scar quality, particularly pigmentation, pliability, and relief, and can represent a valuable option for postoperative scar management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.